Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, July 25th. Analysts expect the company to announce earnings of $0.36 per share for the quarter.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, April 27th. The pharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.09. The company had revenue of $714.72 million during the quarter, compared to analysts’ expectations of $692.64 million. Vertex Pharmaceuticals had a net margin of 8.64% and a return on equity of 3.00%. Vertex Pharmaceuticals’s quarterly revenue was up 79.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.09 earnings per share. On average, analysts expect Vertex Pharmaceuticals to post $0.51 EPS for the current fiscal year and $1.53 EPS for the next fiscal year.
Shares of Vertex Pharmaceuticals Incorporated (VRTX) opened at 163.17 on Monday. The stock has a 50 day moving average of $130.33 and a 200-day moving average of $107.19. Vertex Pharmaceuticals Incorporated has a 12 month low of $71.46 and a 12 month high of $167.00. The company has a market cap of $40.64 billion, a PE ratio of 227.57 and a beta of 1.74.
In other news, EVP Stuart A. Arbuckle sold 70,969 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $128.06, for a total transaction of $9,088,290.14. Following the completion of the sale, the executive vice president now owns 145,061 shares in the company, valued at approximately $18,576,511.66. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Amit Sachdev sold 28,625 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $160.93, for a total value of $4,606,621.25. Following the sale, the executive vice president now owns 119,335 shares of the company’s stock, valued at approximately $19,204,581.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 884,674 shares of company stock valued at $127,947,355. Corporate insiders own 1.80% of the company’s stock.
VRTX has been the subject of several recent research reports. Robert W. Baird reissued an “outperform” rating and issued a $115.00 price objective on shares of Vertex Pharmaceuticals in a report on Wednesday, March 29th. Vetr raised Vertex Pharmaceuticals from a “strong sell” rating to a “strong-buy” rating and set a $156.00 price objective for the company in a report on Tuesday, July 18th. BMO Capital Markets raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $89.67 to $100.00 in a report on Wednesday, March 29th. Jefferies Group LLC reissued a “buy” rating and issued a $185.00 price objective (up previously from $155.00) on shares of Vertex Pharmaceuticals in a report on Wednesday, July 19th. Finally, Credit Suisse Group lifted their price objective on Vertex Pharmaceuticals from $125.00 to $195.00 and gave the stock an “outperform” rating in a report on Wednesday, July 19th. Four equities research analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $158.16.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
